The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer.
Kim, S T; Do, I-G; Lee, J; Sohn, I; Kim, K-M; Kang, W K.
Clin Transl Oncol
; 17(6): 462-8, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25445175
The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer
Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.
Prediktivní a prognostické faktory karcinomu zaludku.
A randomized phase II study of S-1 versus capecitabine as first-line chemotherapy in elderly metastatic gastric cancer patients with or without poor performance status: clinical and pharmacogenetic results.
Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
PCR-sequencing is a complementary method to amplification refractory mutation system for EGFR gene mutation analysis in FFPE samples.
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations